News
LCTX
1.150
-4.17%
-0.050
Weekly Report: what happened at LCTX last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at LCTX last week (0401-0405)?
Weekly Report · 04/08 11:30
LINEAGE ANNOUNCES APPOINTMENT OF CHARLOTTE HUBBERT, PH.D., AS VICE PRESIDENT OF CORPORATE DEVELOPMENT
Reuters · 04/01 12:00
Weekly Report: what happened at LCTX last week (0325-0329)?
Weekly Report · 04/01 11:27
These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
TipRanks · 03/28 14:30
Weekly Report: what happened at LCTX last week (0318-0322)?
Weekly Report · 03/25 11:31
Lineage Cell Therapeutics Inc May Offer And Sell Common Shares Of Up To $40M From Time To Time Through Or To B. Riley
Benzinga · 03/22 20:36
Lineage Cell Therapeutics Entered Into Sales Agreement With B. Riley Securities; Effective As Of March 18 Controlled Equity Offering Sales Agreement Between Co And Cantor Fitzgerald & Co. Was Terminated; On March 12 Received Written Correspondence From U.S. FDA Regarding Its Ind As Amended For OPC1; Per Correspondence, FDA Advised That Company Not Initiate Proposed Clinical Study Until It Has Received FDA Feedback; FDA Anticipates Providing Feedback By April 26, 2024
Benzinga · 03/22 20:29
Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release
TipRanks · 03/19 05:46
Weekly Report: what happened at LCTX last week (0311-0315)?
Weekly Report · 03/18 11:29
Lineage Cell Therapeutics, Inc. Announces RG6501 (OpRegen) Phase 1/2a Clinical Study 24 Month Results To Be Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit
24 month results from patients with geographic atrophy secondary to age-related macular degeneration will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit. OpRegen is a suspension of allogeneic retinal pigment epithelial cells in development for the treatment of GA secondary to AMD.
Benzinga · 03/13 12:13
Buy Rating Affirmed: Lineage Therap’s Growth and Innovation Poised to Transform Biotech Landscape
TipRanks · 03/12 19:15
Lineage Cell Therapeutics Announces OpRegen Preclinical Engraftment Results To Be Presented At 2024 Association For Research In Vision And Ophthalmology Meeting
OpRegen is being developed for the treatment of geographic atrophy secondary to age-related macular degeneration. The preclinical results will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting in Seattle, WA. OpRegen (RG6501) is a suspension of allogeneic retinal pigmented epithelial cells.
Benzinga · 03/11 12:06
Weekly Report: what happened at LCTX last week (0304-0308)?
Weekly Report · 03/11 11:25
Buy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy Advancements
Lineage Cell Therapeutics is a company developing regenerative cell therapies for degenerative retinal diseases. OpRegen has shown the ability to stabilize and potentially improve vision in patients with geographic atrophy. Robert W. Baird analyst Jack Allen has maintained a Buy rating on the stock.
TipRanks · 03/11 04:35
Optimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic Partnerships
Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated price target is $4.00. The company’s phase IIa study of OpRegen for the treatment of Dry AMD is making strides.
TipRanks · 03/08 17:45
Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy Results
TipRanks · 03/08 11:29
Lineage Cell Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 11:24
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target
Benzinga · 03/08 11:12
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
Lineage Cell Therapeutics just reported results for the fourth quarter of 2023. The company reported earnings per share of -3 cents and revenue of $2.10 million. This was 60.31% better than the analyst estimate for revenue of -4 cents.
Investorplace · 03/08 02:55
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.